Fluorescent Probe Compounds for Tumor-Targeted Imaging and Synthesis Methods
Summary
USPTO published patent application US20260097137A1 by Hebei Medical University for fluorescent probe compounds utilizing a pyrrolo[2,3-d]pyrimidine core structure conjugated to a fluorescent dye for tumor-targeted imaging. The probes demonstrate high affinity and selectivity for tumor cells, rapid clearance from normal tissues, and prolonged retention at tumor sites. The invention enables in vitro and in vivo tracking, receptor affinity studies, and intraoperative navigation applications.
What changed
USPTO published patent application US20260097137A1 for fluorescent probe compounds designed for tumor-targeted imaging. The application discloses compounds using an antitumor drug comprising a pyrrolo[2,3-d]pyrimidine core structure as a targeting ligand conjugated to a fluorescent dye through a linker moiety.
Affected parties including research institutions, pharmaceutical companies, and medical device manufacturers developing tumor imaging technologies should monitor this patent publication. It represents potential prior art for similar innovations and may inform competitive IP strategies in the fluorescent probe and surgical navigation space.
What to do next
- Monitor for patent grant status
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FLUORESCENT PROBE COMPOUNDS FOR TUMOR TARGETING IMAGING, AND SYNTHESIS METHOD THEREFOR
Application US20260097137A1 Kind: A1 Apr 09, 2026
Assignee
HEBEI MEDICAL UNIVERSITY
Inventors
Lei WANG, Yining ZHANG, Zijun LUO, Lixiao GUO, Yi LIU, Huicai GUO, Ran GUO, Jing WANG, Qingzhong JIA
Abstract
The present invention relates to fluorescent probe compounds for tumor-targeted imaging, and methods of synthesis and use thereof. The compounds utilize, for the first time, an antitumor drug comprising a pyrrolo[2,3-d]pyrimidine core structure as a targeting ligand, which is conjugated to a fluorescent dye through a linker moiety. The structure of the compound is shown in Formula I. The compound demonstrates high affinity and selectivity for tumor cells expressing target receptors, enabling localization, qualitative and quantitative analysis through in vitro and in vivo tracking, receptor affinity studies, and mechanism of action investigations, thereby exhibiting high specificity, sensitivity, and visualization capability. The fluorescent probe of the present invention achieves rapid clearance from normal tissues while maintaining prolonged retention at tumor sites, thereby enabling in vivo diagnostic functionality. It demonstrates substantial clinical application potential for clinical intraoperative navigation.
CPC Classifications
A61K 49/0052 A61K 49/0032 A61K 49/0043 A61P 35/00
Filing Date
2025-12-11
Application No.
19415861
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.